Recent

% | $
Quotes you view appear here for quick access.

Novavax, Inc. Message Board

  • yes3434 yes3434 Oct 22, 2013 8:43 PM Flag

    charlie rose show tonight

    Craig Venter is an American biologist and entrepreneur. He is known for being one of the first to sequence the human genome and for creating the first cell with a synthetic genome.

    he talked about barda and cell base vaccine 30 min into the show

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Yes3434... This excellent article you mention has been available on the Novavax website since September.
      Just check under "Publications."

      Word to the wise... There are plenty of other good articles under "Publications" too.

      In any case... The article from "The Bio-Processing Journal" It's well worth reading.

      Thanks & Good Luck.

    • Link to the replay not yet up on NPR website.. Anyone know where a transcript is available if that's ready yet?

    • Unfortunately, not NVAX...
      CDC, BARDA Enlist Venter Institute to Combat H7N9
      Synthetic Genomics Vaccines working with Novartis to synthesize genes of new virus.
      DANIEL S. LEVINE The Burrill Report
      “The early availability of these synthetic genes could more rapidly and effectively assist in a global response to an emerging flu strain.”
      The J. Craig Venter Institute, in collaboration with Venter’s Synthetic Genomics Vaccines and Novartis, is working to reverse engineer a vaccine against a new viral strain of bird flu that has killed nine and infected at least 28 people in China.
      Though the virus has been transmitted from birds to humans, there is no documented case of human-to-human transmission of the virus at this time. In a media briefing April 5, the U.S. Centers for Disease Control and Prevention said because researchers have access to the genetic code of the new viral strain, it’s possible to reverse engineer the virus to develop a potential vaccine strain.
      “Under this contract, the synthetic genes were created for BARDA and they are being shared. We are using them to try to develop a candidate vaccine strain as are companies,” says Mike Shaw, director of the CDC’s influenza laboratory. “There are many different approaches to this. Many different companies and organizations are trying to work as quickly as possible to get the strain that would be shared as widely as possible to make sure that the vaccine production could receive it as quickly as possible.”
      J. Craig Venter, chairman of the eponymous institute and CEO of Synthetic Genomic Vaccines, said that his organizations are using virus gene sequences made publicly available through the Global Initiative on Sharing Avian Influenza Data. With the pharma giant Novartis, the organizations are working to synthesize the genes and provide them to CDC.
      “The early availability of these synthetic genes could more rapidly and effectively assist in a global response to an emerging flu strain,” says Venter.

      • 1 Reply to birdyvax
      • That's the live weakened virus approach which has serious problems and which NVAX's VLP approach is far superior to. What's going on here is that the CDC and BARDA are so concerned about the new influenzas that they are pushing on ALL fronts, even that one. When you are faced with imminent attack by an opponent with greatly superior arms, you develop everything you can at maximum speed in the hope that some breakthrough or the combination will be enough.

        NVAX has the superior fundamental approach to vaccines and NNVC by far the most superior approach to treatment (and we will need both, which is why I'm invested in both).

        Until an approach is PROVEN that "push forward at max speed on all fronts" approach will continue. But once something is proven then resources will be shifted from most of the others into it. (work on #2 will continue as a backup).

    • goog this - craig venter novavax -look at the second site from the top pdf file

 
NVAX
5.24-0.21(-3.85%)Apr 29 4:00 PMEDT